sss17
Small moleculeexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2020 (NCT04317833)
Timeline
Indications
Mechanism of action
P4HTM inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07007936 | Phase 2 | Jul 31, 2025 | Sunshine Lake Pharma Co., Ltd. |
| NCT07025915 | Phase 1 | Jun 30, 2025 | Sunshine Lake Pharma Co., Ltd. |
| NCT07024888 | Phase 1 | Mar 16, 2025 | Sunshine Lake Pharma Co., Ltd. |
| NCT07014631 | Phase 2 | Mar 1, 2023 | Sunshine Lake Pharma Co., Ltd. |
| NCT04893187 | Phase 1 | Jun 15, 2021 | Guangzhou Medical University, Sunshine Lake Pharma Co., Ltd. |
| NCT04317833 | Phase 1 | May 1, 2020 | Sunshine Lake Pharma Co., Ltd. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sunshine Lake Pharma Co., Ltd. | For profit | 6 | 6 | 2 | 2020 |
| Guangzhou Medical University | Academic/Hospital | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1